211 related articles for article (PubMed ID: 24582432)
1. The role of regulatory T-cells in glioma immunology.
Ooi YC; Tran P; Ung N; Thill K; Trang A; Fong BM; Nagasawa DT; Lim M; Yang I
Clin Neurol Neurosurg; 2014 Apr; 119():125-32. PubMed ID: 24582432
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of immune evasion by gliomas.
Rolle CE; Sengupta S; Lesniak MS
Adv Exp Med Biol; 2012; 746():53-76. PubMed ID: 22639159
[TBL] [Abstract][Full Text] [Related]
3. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.
Heimberger AB; Abou-Ghazal M; Reina-Ortiz C; Yang DS; Sun W; Qiao W; Hiraoka N; Fuller GN
Clin Cancer Res; 2008 Aug; 14(16):5166-72. PubMed ID: 18698034
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-17 facilitates the immune suppressor capacity of high-grade glioma-derived CD4 (+) CD25 (+) Foxp3 (+) T cells via releasing transforming growth factor beta.
Liang H; Yi L; Wang X; Zhou C; Xu L
Scand J Immunol; 2014 Aug; 80(2):144-50. PubMed ID: 24813240
[TBL] [Abstract][Full Text] [Related]
5. The role of regulatory T cells in malignant glioma.
Sonabend AM; Rolle CE; Lesniak MS
Anticancer Res; 2008; 28(2B):1143-50. PubMed ID: 18505050
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of interleukin-10 or transforming growth factor-β decreases the percentages of CD4+ CD25+ Foxp3+ regulatory T cells in septic mice, thereby leading to an improved survival.
Hiraki S; Ono S; Tsujimoto H; Kinoshita M; Takahata R; Miyazaki H; Saitoh D; Hase K
Surgery; 2012 Feb; 151(2):313-22. PubMed ID: 21982068
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
[TBL] [Abstract][Full Text] [Related]
8. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
[TBL] [Abstract][Full Text] [Related]
9. Investigation of immunosuppressive mechanisms in a mouse glioma model.
Ksendzovsky A; Feinstein D; Zengou R; Sharp A; Polak P; Lichtor T; Glick RP
J Neurooncol; 2009 May; 93(1):107-14. PubMed ID: 19430886
[TBL] [Abstract][Full Text] [Related]
10. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg.
Biollaz G; Bernasconi L; Cretton C; Püntener U; Frei K; Fontana A; Suter T
Eur J Immunol; 2009 May; 39(5):1323-33. PubMed ID: 19337997
[TBL] [Abstract][Full Text] [Related]
11. Immune defects observed in patients with primary malignant brain tumors.
Dix AR; Brooks WH; Roszman TL; Morford LA
J Neuroimmunol; 1999 Dec; 100(1-2):216-32. PubMed ID: 10695732
[TBL] [Abstract][Full Text] [Related]
12. Alteration in frequency and function of CD4⁺CD25⁺FOXP3⁺ regulatory T cells in patients with immune thrombocytopenic purpura.
Arandi N; Mirshafiey A; Jeddi-Tehrani M; Shaghaghi M; Sadeghi B; Abolhassani H; Sharifian RA; Rahiminejad MS; Aghamohammadi A
Iran J Allergy Asthma Immunol; 2014 Apr; 13(2):85-92. PubMed ID: 24338252
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells.
Taylor A; Verhagen J; Blaser K; Akdis M; Akdis CA
Immunology; 2006 Apr; 117(4):433-42. PubMed ID: 16556256
[TBL] [Abstract][Full Text] [Related]
14. Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors.
Morford LA; Dix AR; Brooks WH; Roszman TL
J Neurosurg; 1999 Dec; 91(6):935-46. PubMed ID: 10584838
[TBL] [Abstract][Full Text] [Related]
15. Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model.
Panek WK; Pituch KC; Miska J; Kim JW; Rashidi A; Kanojia D; Lopez-Rosas A; Han Y; Yu D; Chang CL; Kane JR; Zhang P; Cordero A; Lesniak MS
Mol Neurobiol; 2019 Jul; 56(7):5032-5040. PubMed ID: 30460615
[TBL] [Abstract][Full Text] [Related]
16. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Jordan JT; Sun W; Hussain SF; DeAngulo G; Prabhu SS; Heimberger AB
Cancer Immunol Immunother; 2008 Jan; 57(1):123-31. PubMed ID: 17522861
[TBL] [Abstract][Full Text] [Related]
17. [The immunosuppressive microenvironment of malignant gliomas].
Borisov KE; Sakaeva DD
Arkh Patol; 2015; 77(6):54-63. PubMed ID: 26841651
[TBL] [Abstract][Full Text] [Related]
18. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
Wainwright DA; Balyasnikova IV; Chang AL; Ahmed AU; Moon KS; Auffinger B; Tobias AL; Han Y; Lesniak MS
Clin Cancer Res; 2012 Nov; 18(22):6110-21. PubMed ID: 22932670
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of central and peripheral immunomodulation in a murine glioma model.
Kennedy BC; Maier LM; D'Amico R; Mandigo CE; Fontana EJ; Waziri A; Assanah MC; Canoll P; Anderson RC; Anderson DE; Bruce JN
BMC Immunol; 2009 Feb; 10():11. PubMed ID: 19226468
[TBL] [Abstract][Full Text] [Related]
20. Expression of tumor necrosis factor-α induced protein 8 like-2 contributes to the immunosuppressive property of CD4(+)CD25(+) regulatory T cells in mice.
Luan YY; Yao YM; Zhang L; Dong N; Zhang QH; Yu Y; Sheng ZY
Mol Immunol; 2011 Oct; 49(1-2):219-26. PubMed ID: 21963221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]